{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=imiquimod", "query": { "intervention": "imiquimod" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 93, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=imiquimod&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T17:24:09.130Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01909752", "title": "Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "DRibble vaccine", "type": "BIOLOGICAL" }, { "name": "Imiquimod", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "HPV vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "UbiVac", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-07", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 2, "location_summary": "New Orleans, Louisiana • Portland, Oregon", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01909752" }, { "nct_id": "NCT00335179", "title": "Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Actinic Keratosis" ], "interventions": [ { "name": "Aldara (imiquimod 5% cream)", "type": "DRUG" }, { "name": "Vehicle cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Graceway Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 17, "start_date": "2003-01", "completion_date": "2003-07", "has_results": false, "last_update_posted_date": "2010-07-23", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335179" }, { "nct_id": "NCT02078648", "title": "Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Brain Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "SL-701 + GM-CSF", "type": "DRUG" }, { "name": "Imiquimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stemline Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2014-05", "completion_date": "2018-01-22", "has_results": true, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02078648" }, { "nct_id": "NCT01203878", "title": "Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Actinic Keratosis" ], "interventions": [ { "name": "Photodynamic therapy", "type": "DRUG" }, { "name": "Imiquimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tennessee Clinical Research Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2010-09", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2014-12-08", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 3, "location_summary": "Englewood, Colorado • Charlotte, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Englewood", "state": "Colorado" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01203878" }, { "nct_id": "NCT02234921", "title": "Pilot Study of DRibble Vaccine for Prostate Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Prostate" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "DRibble Vaccine", "type": "BIOLOGICAL" }, { "name": "HPV Vaccinations", "type": "BIOLOGICAL" }, { "name": "Imiquimod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "UbiVac", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 3, "start_date": "2014-10-24", "completion_date": "2018-08-15", "has_results": false, "last_update_posted_date": "2018-10-11", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02234921" }, { "nct_id": "NCT01403285", "title": "Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IMA950 plus GM-CSF", "type": "BIOLOGICAL" }, { "name": "IMA950", "type": "BIOLOGICAL" }, { "name": "Imiquimod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Immatics Biotechnologies GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-08", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-05-19", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01403285" }, { "nct_id": "NCT02120898", "title": "A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Actinic Keratosis" ], "interventions": [ { "name": "Imiquimod", "type": "DRUG" }, { "name": "Zyclara®", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 467, "start_date": "2013-10-10", "completion_date": "2014-04-30", "has_results": true, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120898" }, { "nct_id": "NCT00735462", "title": "Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Genital Warts" ], "interventions": [ { "name": "2.5% imiquimod cream", "type": "DRUG" }, { "name": "3.75% imiquimod cream", "type": "DRUG" }, { "name": "Placebo cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Graceway Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 511, "start_date": "2008-08", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2011-07-20", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 43, "location_summary": "Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" }, { "city": "Chico", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00735462" }, { "nct_id": "NCT00453050", "title": "Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)", "Metastatic Cancer" ], "interventions": [ { "name": "imiquimod", "type": "DRUG" }, { "name": "indocyanine green solution", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-06", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 1, "location_summary": "Tulsa, Oklahoma", "locations": [ { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00453050" }, { "nct_id": "NCT00799110", "title": "Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "GM-CSF", "type": "DRUG" }, { "name": "Dendritic Cell/Tumor Fusion Vaccine", "type": "BIOLOGICAL" }, { "name": "imiquimod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2008-05", "completion_date": "2025-09", "has_results": true, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-03T17:24:09.130Z", "location_count": 4, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00799110" } ] }